




Multimedia
Publishing
mmp.elsevier.com

Craig Smith, Senior Editor
Multimedia Publishing
360 Park Avenue South
New York, NY 10010
Tel: 212-462-1933; Fax: 212-633-3820
Email: c.smith@elsevier.com



GUIDELINES FOR SUPPLEMENT PUBLICATION

Supplements to Elsevier journals are designed to serve an educational purpose for the subscribers and readers of the *Journal* and other healthcare professionals. The goal of supplement publications is to provide fair, balanced information of high scientific quality. Supplements to a *Journal* are produced through the financial support of medical education companies, pharmaceutical companies, device and equipment companies, non-profit and governmental organizations, and their designates. The following are general guidelines for publication of supplements:

1. Organizations considering publication of a sponsored supplement should consult with the editorial staff of the *Journal* to make certain the educational objectives and value of the supplement are optimized during the planning process. All supplements will be prospectively reviewed by the *Journal*.
2. Supplements must have educational value and be useful to the *Journal* readership to be considered for publication.
3. Supplements should primarily emphasize broad topics (disease/disorders; e.g., CAD or congestive heart failure rather than specific drugs). Supplements devoted to classes of drugs rather than a specific agent will be given priority. In general, product-oriented publications will not receive serious consideration unless there are compelling reasons or unique properties of the drug (product) that justifies its publication. The topic must be treated in an impartial, unbiased manner.
4. The authors are solely responsible for the content of their manuscripts and the opinions expressed. They are also responsible for the replicability, precision, and integrity of the data and may be asked to sign a statement to that effect prior to publication. All authors are required to fully disclose any primary financial relationship with a company that has a direct fiscal or financial interest in the subject matter or products discussed in submitted manuscripts, or with a company that produces a competing product.
5. Authors are required to disclose the name of any company that has provided any editorial support in the development of their manuscript. Further they are required to disclose any funding that company may have received for manuscript development. If writing assistance was provided by persons who do not meet the criteria of authorship as described in the International Committee of Medical Journal Editors (<http://www.icmje.org/#author>), the authors must disclose the identity of the individuals who provided this assistance and the entity that provided any financial support of this assistance.
6. All supplement manuscripts will undergo editorial and/or peer review as determined by the *Journal* editorial office to consider the overall educational value of the manuscript and the scientific validity and reliability of new (not previously published) data (rationale/background; purpose; patients; location; experimental design; intervention(s); results; conclusions; etc.). Manuscripts determined to be unacceptable after the review process will be rejected for publication.
7. Sponsorship and support will be disclosed on the supplement cover or supplement front matter pages. Organizers and sponsors will be responsible for complying, and agree to comply, with all federal, state and local laws, rules and regulations that may be applicable in connection with sponsorship and support of the supplement.